Wafra Inc. Increases Stock Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wafra Inc. lifted its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 53,877 shares of the biopharmaceutical company's stock after purchasing an additional 23,811 shares during the period. Wafra Inc.'s holdings in Halozyme Therapeutics were worth $1,991,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the company. Quadrant Capital Group LLC grew its position in shares of Halozyme Therapeutics by 22.4% in the 4th quarter. Quadrant Capital Group LLC now owns 3,414 shares of the biopharmaceutical company's stock worth $126,000 after buying an additional 624 shares during the last quarter. Torray Investment Partners LLC raised its holdings in Halozyme Therapeutics by 53.4% in the 4th quarter. Torray Investment Partners LLC now owns 39,886 shares of the biopharmaceutical company's stock worth $1,474,000 after purchasing an additional 13,881 shares in the last quarter. Janney Montgomery Scott LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $473,000. Vanguard Personalized Indexing Management LLC lifted its position in shares of Halozyme Therapeutics by 86.0% in the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 20,050 shares of the biopharmaceutical company's stock worth $741,000 after purchasing an additional 9,272 shares during the period. Finally, Boston Partners boosted its stake in shares of Halozyme Therapeutics by 562.2% during the 4th quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company's stock valued at $20,218,000 after purchasing an additional 468,977 shares in the last quarter. 97.79% of the stock is owned by hedge funds and other institutional investors.

Halozyme Therapeutics Stock Down 1.5 %

NASDAQ:HALO traded down $0.68 on Friday, reaching $44.71. 1,102,299 shares of the stock traded hands, compared to its average volume of 989,383. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. The company has a market capitalization of $5.69 billion, a price-to-earnings ratio of 18.48, a PEG ratio of 0.51 and a beta of 1.26. Halozyme Therapeutics, Inc. has a 12 month low of $31.86 and a 12 month high of $46.16. The company's fifty day simple moving average is $40.53 and its 200 day simple moving average is $38.51.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings results on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing the consensus estimate of $0.77 by ($0.02). The firm had revenue of $230.04 million for the quarter, compared to the consensus estimate of $235.25 million. Halozyme Therapeutics had a net margin of 36.94% and a return on equity of 225.71%. Equities analysts predict that Halozyme Therapeutics, Inc. will post 3.44 EPS for the current fiscal year.

Insider Activity

In related news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $39.55, for a total value of $395,500.00. Following the completion of the sale, the senior vice president now directly owns 156,558 shares in the company, valued at approximately $6,191,868.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 30,000 shares of company stock valued at $1,196,800 over the last ninety days. 2.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have commented on HALO shares. StockNews.com upgraded shares of Halozyme Therapeutics from a "hold" rating to a "buy" rating in a report on Friday, February 23rd. TheStreet cut Halozyme Therapeutics from a "b-" rating to a "c+" rating in a research note on Monday, January 22nd. TD Cowen started coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an "outperform" rating and a $54.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $50.00 target price on shares of Halozyme Therapeutics in a report on Tuesday, May 7th. Finally, JMP Securities decreased their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 8th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $53.14.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.